CDH3

Across TCGA pan-cancer cohorts, CDH3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDH3 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CDH3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

CESC, LUSC, and OV are the cancer types where CDH3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	30	view →
LUSC	OS	Median	III,IV	0.011	0.684	<.001	21	view →
OV	DFS	Median	All	0.198	0.542	.001	18	view →
HNSC	OS	Median	IV	0.209	0.610	.002	12	view →
BLCA	OS	Median	IV	0.130	0.599	.028	6	view →
SKCM	DFS	Median	All	0.706	0.195	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDH3–CESC (OS)

Open the CESC breakdown →